Stock Detail
NYMOX PHARMACEUTICAL CORPORATION
Sector: Biotechnology
Latest Quote @ Fri May 5 05:03:55 (15 min delayed)
| N/A |
N/A |
$5.23 |
+0.04 |
0.77% |
|
Last Day's Data
| $5.23 |
$5.23 |
$0.04 |
0.77% |
0.00 |
$5.19 |
| $5.05 |
$5.03 |
10,780.00 |
175.20M |
66,720.00 |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 5.36 |
5.29 |
5.16 |
5.09 |
4.96 |
Stock Profile
Nymox Pharmaceutical Corporation, through its subsidiaries, engages in the research and development of products for the diagnosis and treatment of Alzheimer's disease. The company markets AlzheimAlert, a urinary test that helps physicians in the diagnosis of Alzheimer's disease. It also markets NicAlert and TobacAlert tests that use urine or saliva to detect the use of tobacco products. In addition, Nymox develops therapeutics for the treatment of Alzheimer's disease; treatments for benign prostate hyperplasia; and anti-bacterial agents for the treatment of urinary tract and other bacterial infections in humans, including a treatment for E. coli O157:H7 bacterial contamination in meat and other food and drink products. The company was founded by Paul Averback in 1989 and is based in St. Laurent, Canada.
